0001567619-19-006615.txt : 20190311 0001567619-19-006615.hdr.sgml : 20190311 20190311191054 ACCESSION NUMBER: 0001567619-19-006615 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190307 FILED AS OF DATE: 20190311 DATE AS OF CHANGE: 20190311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANAN MICHAEL F CENTRAL INDEX KEY: 0001461953 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 19673585 MAIL ADDRESS: STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 doc1.xml FORM 4 X0306 4 2019-03-07 0 0001012477 AVADEL PHARMACEUTICALS PLC FLML 0001461953 KANAN MICHAEL F BLOCK 10-1, BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN DUBLIN L2 15 IRELAND 0 1 0 0 See Remarks ADSs 2019-03-07 4 A 0 18000 0 A 50538 D Stock Option (right to buy) 16.21 2025-10-28 ADSs 100000 100000 D Stock Option (right to buy) 10.4 2026-12-14 ADSs 100000 100000 D Stock Option (right to buy) 8.95 2027-12-12 ADSs 80000 80000 D Stock Option (right to buy) 1.85 2019-03-07 4 A 0 80000 1.85 A 2029-03-07 ADSs 80000 80000 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Includes (a) 18,000 ADSs granted under the issuer's "Free Share" award program as restricted ADSs on 12/14/2016, all of which were issued to the reporting person on the second anniversary of the grant date; in connection with the payment of certain withholding taxes related to such issuance, the reporting person sold 8,429 ADSs on December 14, 2018; (b) 18,000 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 12,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 6,000 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); (c) 3,000 ADSs acquired under the issuer's 2017 Employee Share Purchase Plan on 1/8/2019; and [continued in footnote 3 below] (d) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary). Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 10/28/2015 grant date. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date. Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date. Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date. Sr. VP, Chief Financial Officer. /s/ Phillandas T. Thompson, as attorney-in-fact for Michael F. Kanan 2019-03-11